Currently out of the existing stock ratings of Colin Bristow, 68 are a BUY (57.14%), 51 are a HOLD (42.86%).

Colin Bristow

Work Performance Price Targets & Ratings Chart

Analyst Colin Bristow, currently employed at UBS, carries an average stock price target met ratio of 57.48% that have a potential upside of 15.49% achieved within 207 days.

Colin Bristow’s has documented 238 price targets and ratings displayed on 21 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on PTCT, PTC Therapeutics at 03-Dec-2024.

Wall Street Analyst Colin Bristow

Analyst best performing recommendations are on OMER (OMEROS).
The best stock recommendation documented was for IMVT (IMMUNOVANT ) at 9/26/2022. The price target of $5 was fulfilled within 3 days with a profit of $0.48 (10.62%) receiving and performance score of 35.4.

Average potential price target upside

of $144.94 (18.11%) on REGN (REGENERON PHARMACEUTICALS).
of $63.52 (23.87%) on VRTX (VERTEX PHARMACEUTICALS).
of $47.04 (29.77%) on LLY (ELI LILLY AND COMPANY).

ALXN Alexion Pharmaceuticals AMGN Amgen BIIB Biogen BTAI BioXcel Therapeutics GILD Gilead Sciences LLY Eli Lilly and Company MRK Merck mpany MTEM Molecular Templates OMER Omeros PFE Pfizer PTCT PTC Therapeutics SRPT Sarepta Therapeutics VRTX Vertex Pharmaceuticals ABBV AbbVie CCCC C4 Therapeutics BMY Bristol-Myers Squibb Company RCKT Rocket Pharmaceuticals ALXO Alx Oncology Holdings IMVT Immunovant REGN Regeneron Pharmaceuticals ABOS Acumen Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hartaj Singh (OPPENHEIMER)